Destiny Pharma (LON:DEST) announced Monday they are commencing US clinical trials for its novel anti-infective drug XF-73, after the FDA accepted the Investigational New Drug application.
The anti-infective drug is being developed to prevent post-surgical staphylococcal infections in patients such as Methicillin Resistant Staphylococcus aureus (MRSA).
“We are pleased to open the IND and are looking forward to starting the clinical programme and reporting the Phase 2 data in 2019. The US is the largest potential market for this drug candidate and XF-73 could be the first drug approved for the US FDA’s newly defined indication of “prevention of post-surgical staphylococcal infection”. We look forward to continuing to advance XF-73 through clinical development,” said CEO, Neil Clark.
The XF-73 drug has been developed from Destiny Pharma’s novel, antimicrobial “XF” drug platform and was awarded Qualifying Infectious Disease Product (QIDP) status in October 2015 by the US FDA.
Destiny Pharma is a UK clinical stage biotechnology company focused on the development of anti-microbial drugs, which addresses the global problem of anti-microbial resistance.
The pharmaceutical launched a £15.3 million IPO on the London Stock Exchange’s AIM market last September 2017. Following the news, shares were up 3.05 percent, trading at 135p, as of 14:30 (GMT).
